Article | January 4, 2022

Rewriting The Health Code: How mRNA Technology Is Shaping The Future Of Medicine

By Stefan Randl and Maaike Everts, Evonik Health Care


The Covid-19 pandemic has ushered in a new era in medicine – that of mRNA technology. But the potential of mRNA for preventing and treating a whole range of diseases reaches further to infectious diseases, cancer immunotherapy, therapeutics for protein replacement and gene therapy. In this article, we examine how mRNA technologies open the doors to a whole range of new gene therapies and the role of lipid nanoparticles (LNPs) in current and future developments.

There are currently numerous clinical trials taking place for mRNA therapeutics, and these show great potential for tackling diseases. One application is in cancer immunotherapy, where mRNA vaccines can be used to encode tumor-associated antigens that are expressed in cancer cells, thus educating the immune system to eliminate these tumor cells. Another application is to develop therapeutic approaches for autoimmune diseases like multiple sclerosis (MS), where the technology teaches the immune system to tolerate the natural proteins attacking the immune system.

To make full use of these technologies, we need to ensure the mRNA can be effectively and safely delivered into the cell. Lipid nanoparticles are crucial to the successful delivery of mRNA vaccines and other RNA and nucleic acid therapeutics.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online